Bioventus Inc.
NASDAQ:BVS
7.26 (USD) • At close May 1, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 573.28 | 512.345 | 512.117 | 430.898 | 321.161 | 340.141 | 319.177 | 292.059 | 274.5 | 253.65 | 242.893 | 232.375 | 64.774 |
| Cost of Revenue
| 185.054 | 184.152 | 181.037 | 128.192 | 87.642 | 90.935 | 84.168 | 92.097 | 91.389 | 74.342 | 74.609 | 71.372 | 18.966 |
| Gross Profit
| 388.226 | 328.193 | 331.08 | 302.706 | 233.519 | 249.206 | 235.009 | 199.962 | 183.111 | 179.308 | 168.284 | 161.003 | 45.808 |
| Gross Profit Ratio
| 0.677 | 0.641 | 0.646 | 0.703 | 0.727 | 0.733 | 0.736 | 0.685 | 0.667 | 0.707 | 0.693 | 0.693 | 0.707 |
| Reseach & Development Expenses
| 13.639 | 13.446 | 23.854 | 19.039 | 11.202 | 11.055 | 8.095 | 8.096 | 7.9 | 14.747 | 9.465 | 10.936 | 4.665 |
| General & Administrative Expenses
| 0 | 300.026 | 326.931 | 250.38 | 190.309 | 196.124 | 0 | 0 | 0 | 0 | 0 | 0 | 33.916 |
| Selling & Marketing Expenses
| 0 | 3.853 | 5.203 | 3.873 | 2.769 | 2.351 | 0 | 0 | 0 | 0 | 0 | 0 | 42.901 |
| SG&A
| 340.894 | 303.879 | 332.134 | 254.253 | 193.078 | 198.475 | 191.672 | 164.842 | 160.321 | 148.441 | 147.058 | 150.37 | 76.817 |
| Other Expenses
| 45.672 | 92.593 | 142.326 | 17.353 | 8.002 | 8.483 | 9.738 | 0 | 0 | 10.57 | 8.968 | 7.765 | 0 |
| Operating Expenses
| 400.205 | 409.918 | 498.314 | 290.645 | 212.282 | 218.013 | 209.505 | 172.938 | 168.221 | 173.758 | 165.491 | 169.071 | 81.482 |
| Operating Income
| -11.979 | -81.725 | -167.234 | 12.061 | 21.237 | 31.193 | 25.504 | 27.024 | 14.89 | -16.588 | 0.02 | -8.068 | -35.674 |
| Operating Income Ratio
| -0.021 | -0.16 | -0.327 | 0.028 | 0.066 | 0.092 | 0.08 | 0.093 | 0.054 | -0.065 | 0 | -0.035 | -0.551 |
| Total Other Income Expenses Net
| -37.147 | -39.386 | -21.791 | -2.573 | -5.323 | -21.504 | -19.397 | -18.366 | -20.544 | -15.383 | -11.373 | -12.172 | -3.416 |
| Income Before Tax
| -49.126 | -121.111 | -189.025 | 9.488 | 15.914 | 9.689 | 6.107 | 8.658 | -5.654 | -31.971 | -11.353 | -20.24 | -39.09 |
| Income Before Tax Ratio
| -0.086 | -0.236 | -0.369 | 0.022 | 0.05 | 0.028 | 0.019 | 0.03 | -0.021 | -0.126 | -0.047 | -0.087 | -0.603 |
| Income Tax Expense
| -5.293 | 0.085 | -44.374 | -1.966 | 1.192 | 1.576 | 1.664 | -0.785 | 1.091 | 2.14 | 1.547 | 2.127 | 0.132 |
| Net Income
| -33.542 | -156.23 | -158.704 | 19.375 | 16.411 | 6.851 | -12.207 | -1.639 | -17.953 | -34.111 | -12.9 | -22.367 | -39.222 |
| Net Income Ratio
| -0.059 | -0.305 | -0.31 | 0.045 | 0.051 | 0.02 | -0.038 | -0.006 | -0.065 | -0.134 | -0.053 | -0.096 | -0.606 |
| EPS
| -0.75 | -2.49 | -2.59 | -0.15 | 0.44 | 0.12 | -0.22 | -0.029 | -0.32 | -0.69 | -0.3 | -0.47 | -0.71 |
| EPS Diluted
| -0.75 | -2.49 | -2.59 | -0.15 | 0.44 | 0.12 | -0.22 | -0.029 | -0.32 | -0.69 | -0.3 | -0.4 | -0.71 |
| EBITDA
| -49.555 | -23.07 | -121.606 | 45.475 | 52.065 | 61.584 | 54.516 | 59.847 | 44.045 | 15.184 | 29.302 | 15.677 | -16.482 |
| EBITDA Ratio
| -0.086 | -0.045 | -0.237 | 0.106 | 0.162 | 0.181 | 0.171 | 0.205 | 0.16 | 0.06 | 0.121 | 0.067 | -0.254 |